Ionis Pharmaceuticals, Inc.

NasdaqGS-IONS

Assets	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Cash and Cash Equivalents	297.3	242.1	294	399.3	424.8	276.5
Cash and Cash Equivalents
Short-Term Investments	1,992.7	2,055.6	1,784.7	1,931.9	1,960.6	1,710.4
Short-Term Investments
Total Cash and Cash Equivalents	2,290	2,297.7	2,078.7	2,331.2	2,385.4	1,986.9
Accounts Receivable	52.6	92.2	27.3	97.8	28	25.5
Contracts Receivable
Total Trade Receivables	52.6	92.2	27.3	97.8	28	25.5
Inventories	8.5	12.5	28.7	7.4	25.5	22
Inventories
Other Current Assets	226.1	217.9	194.7	205.4	177.9	168.3
Investment in Regulus Therapeutics Inc.
Other Current Assets
Total Current Assets	2,577.2	2,620.3	2,329.4	2,641.9	2,616.8	2,202.7
Total Current Assets
Net Property, Plant & Equipment	275.9	256.1	242.8	242.9	268.4	255.8
Property, Plant and Equipment, Net
Right-of-Use Assets
Net Intangible Assets	—	—	—	—	—	—
Licenses, Net
Patents, Net
Other Long-Term Assets	132.1	127.3	118.9	105.3	86	75.3
Long-Term Deferred Tax Assets
Deposits and Other Assets
Total Assets	2,985.1	3,003.7	2,691.1	2,990.1	2,971.1	2,533.9
Total Assets

Liabilities	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Accounts Payable	22.8	43	9.2	26	24	17.9
Accounts Payable
Accrued Expenses	145.5	178.1	149.3	215.6	134.1	189.3
Accrued Compensation
Accrued Liabilities
Current Portion of Long-Term Debt	630.1	—	44.4	44.3	—	—
Current Portion of Long-Term Obligations and Other Current Liabilities
1 Percent Convertible Senior Notes, Net
Current Portion of Long-Term Obligations
0.125 Percent Convertible Senior Notes, Net
0 Percent Convertible Senior Notes, Net
Unearned Revenue	75.9	79	94.1	151.1	96.3	90.6
Current Portion of Deferred Contract Revenue
Other Current Liabilities	22.9	9.3	9.1	11	33.6	13.8
Income Taxes Payable
Other Current Liabilities
Total Current Liabilities	897.2	309.3	306.2	448.1	288	311.6
Total Current Liabilities
Long-Term Debt	566.4	1,193.6	1,190.6	1,187.7	1,298.8	1,166.7
2¾ Percent Convertible Senior Notes
1 Percent Convertible Senior Notes
0.125 Percent Convertible Senior Notes, Net
0.125 Percent Convertible Senior Notes
1.75 Percent Convertible Senior Notes, Net
0 Percent Convertible Senior Notes, Net
Long-Term Mortgage Debt
Leases	164.4	161.8	166.4	170.9	175	178.9
Long-Term Lease Liabilities
Long-Term Financing Liability for Leased Facility
Other Long-Term Liabilities	666.3	698.7	722.5	754.9	764.6	287.8
Long-Term Deferred Contract Revenue
Liability Related to Sale of Future Royalties, Net
Total Long-Term Liabilities	59.1	51.9	41.8	41.8	16.4	16
Long-Term Obligations
Total Liabilities	2,353.4	2,415.3	2,427.4	2,603.4	2,542.8	1,961
Total Liabilities

Equity	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Common Stock	0.2	0.2	0.1	0.1	0.1	0.1
Common Stock
Additional Paid-in Capital	2,932.7	2,868.8	2,303.4	2,215.1	2,118.3	2,059.9
Additional Paid-in Capital
Accumulated Other Comprehensive Income	-28	-30.8	-34.8	-32.6	-50.9	-57.5
Accumulated Other Comprehensive Income
Retained Earnings	-2,273.2	-2,249.8	-2,005	-1,795.9	-1,639.2	-1,429.6
Retained Earnings
Total Common Shareholders' Equity	631.7	588.4	263.7	386.7	428.3	572.9
Total Ionis Stockholders' Equity
Minority Interests and Other	—	—	—	—	—	—
Noncontrolling Interest in Akcea Therapeutics, Inc.
Total Shareholders' Equity	631.7	588.4	263.7	386.7	428.3	572.9
Total Stockholders' Equity
Total Stockholders' Equity
Total Liabilities and Shareholders' Equity	2,985.1	3,003.7	2,691.1	2,990.1	2,971.1	2,533.9
Total Liabilities and Stockholders' Equity